Liu Huixin, Yan Wenjun, Xu Gaosi
Medical Center of the Graduate School, Nanchang University , Nanchang , P.R. China and.
Ren Fail. 2014 Oct;36(9):1360-5. doi: 10.3109/0886022X.2014.949559. Epub 2014 Aug 26.
To assess the efficacy of thyroid hormone replacement therapy for nephrotic syndrome (NS) patients associated with euthyroid sick syndrome (ESS).
The Cochrane library, ISI, Ovid, PubMed, Chinese Biomedicine Database were searched, and reference list of relevant articles were selected. Randomized controlled trials (RCTs) or quasi-RCTs with thyroid hormone replacement on NS patients associated with ESS were included in this analysis.
Six trials (329 participants) were included. Meta-analysis showed that thyroid hormone replacement therapy can significantly increase the completely remission rate [OR = 3.04, 95% confidence interval (CI): 3.04-1.88, p < 0.00001] and total response rate (OR = 4.63, 95% CI: 2.46-8.71, p < 0.00001) of NS patients associated with ESS. No side effect was observed during the follow-up period. There was no obvious publication bias in the mete-analysis studies.
Thyroid hormone replacement therapy significantly increases the remission of ESS in patients with NS.
评估甲状腺激素替代疗法对合并正常甲状腺病态综合征（ESS）的肾病综合征（NS）患者的疗效。
检索Cochrane图书馆、ISI、Ovid、PubMed、中国生物医学数据库，并筛选相关文章的参考文献列表。纳入对合并ESS的NS患者进行甲状腺激素替代治疗的随机对照试验（RCT）或半随机对照试验。
纳入6项试验（329名参与者）。荟萃分析表明，甲状腺激素替代疗法可显著提高合并ESS的NS患者的完全缓解率[比值比（OR）=3.04，95%置信区间（CI）：3.04 - 1.88，p < 0.00001]和总缓解率（OR = 4.63，95%CI：2.46 - 8.71，p < 0.00001）。随访期间未观察到副作用。荟萃分析研究中无明显的发表偏倚。
甲状腺激素替代疗法可显著提高NS患者ESS的缓解率。
